Choosing the right medication for the treatment of alcoholism

Current Psychiatry Reports

Volumn 8, Issue 5, 2006, Pages 383-388

  Pettinati, Helen M ^a   Rabinowitz, Amanda R ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACAMPROSATE; DISULFIRAM; MU OPIATE RECEPTOR; NALTREXONE; PLACEBO; QUETIAPINE; TOPIRAMATE; VIVITROL;

ADJUVANT THERAPY; ALCOHOL ABSTINENCE; ALCOHOLISM; BEHAVIOR THERAPY; CLINICAL TRIAL; COST OF ILLNESS; COUNSELING; DRINKING BEHAVIOR; DRUG ALCOHOL INTERACTION; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG CHOICE; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FOOD AND DRUG ADMINISTRATION; GENETIC POLYMORPHISM; HUMAN; META ANALYSIS; NAUSEA AND VOMITING; PATIENT COMPLIANCE; PHARMACEUTICAL CARE; PRESCRIPTION; PROGNOSIS; PSYCHOSOCIAL CARE; REVIEW; SYSTEMATIC REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE;

ALCOHOL DETERRENTS; ALCOHOLISM; CHOICE BEHAVIOR; COGNITIVE THERAPY; COMBINED MODALITY THERAPY; FRUCTOSE; HUMANS; NALTREXONE; NARCOTIC ANTAGONISTS; NEUROPROTECTIVE AGENTS; TAURINE;

EID: 33749477331     PISSN: 15233812     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11920-006-0040-0     Document Type: Review

References (41)

1. Owen PL, Slaymaker V, Tonigan JS, et al.: Participation in Alcoholics Anonymous: intended and unintended change mechanisms. Alcohol Clin Exp Res 2003, 27:524-532.
2. Kadden R, Carroll KM, Donovan D, et al.: Cognitive-Behavioral Coping Skills Therapy Manual: A Clinical Research Guide for Therapists Treating Individuals with Alcohol Abuse and Dependence. Rockville, MD: US Department of Health and Human Services; 1995. [DHHS publication no. 94-3724.]
3. Morganstern J, Morgan TJ, McCrady BS, et al.: Manual-guided cognitive-behavioral therapy training: a promising method for disseminating empirically supported substance abuse treatments to the practice community. Psychol Addict Behav 2001, 12:83-88.
4. Miller WR, Zweben A, DiClemente CC, Rychtarik RG: Motivational Enhancement Therapy Manual: A Clinical Research Guide for Therapists Treating Individuals with Alcohol Abuse and Dependence. Rockville, MD: US Department of Health and Human Services; 1994. Project MATCH Monograph Series, Vol 2, No. 94-3723.
5. Miller WR, Rollnick S: Motivational Interviewing: Preparing People to Change Addictive Behavior. New York: Guilford Press; 1991.
6. Fuller RK, Branchery L, Brightwell DR, et al.: Disulfiram treatment of alcoholism: a Veterans Administration cooperative study. JAMA 1986, 256:1449-1455.
7. Suh JJ, Pettinati HM, Kampman KM, O'Brien CP: The status of disulfiram: a half of a century later. J Clin Psychopharmacol 2006, 23:290-302.
8. Mark TL, Kranzler HR, Poole VH, et al.: Barriers to the use of medications to treat alcoholism. Am J Addict 2003, 12:281-294.
9. Pettinati HM, Monterosso J, Lipkin C, Volpicelli JR: Patient attitudes toward treatment predict attendance in clinical pharmacotherapy trials of alcohol and drug treatment. Am J Addict 2003, 12:324-335.
10. Volpicelli JR, Rhines KC, Rhines JS, et al.: Naltrexone and alcohol dependence: role of subject compliance. Arch Gen Psychiatry 1997, 54:737-742.
11. Spanagel R, Holter SM, Allingham K, et al.: Acamprosate and alcohol: I. Effects on alcohol intake following alcohol deprivation in the rat. Eur J Pharmacol 1996, 305:39-44.
12. Spanagel R, Putzke J, Stefferl A, et al.: Acamprosate and alcohol: II. Effects on alcohol withdrawal in the rat. Eur J Pharmacol 1996, 305:45-50.
13. Garbutt JC, Kranzler HR, O'Malley SS, et al.: Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial. JAMA 2005, 293:1617-1625.
14. Anton RF, O'Malley SS, Ciraulo DA, et al.: Combined pharmacotherapies and behavioral interventions for alcohol dependence. The COMBINE study: a randomized controlled trial. JAMA 2006, 295:2003-2017.
15. Pettinati HM, Volpicelli JR, Pierce JD, Jr, O'Brien CP: Improving naltrexone response: an intervention for medical practitioners to enhance medication compliance in alcohol dependent patients. J Addict Dis 2000, 19:71-83.
16. O'Brien CP, Volpicelli LA, Volpicelli JR: Naltrexone in the treatment of alcoholism: a clinical review. Alcohol 1996, 13:35-39.
17. Oslin DW, Berrettini W, Kranzler HR, et al.: A functional polymorphism of the mu-opioid receptor gene is associated with naltrexone response in alcohol-dependent patients. Neuropsychopharmacology 2003, 28:1546-1552.
18. Gianoulakis C, Béliveau D, Angelogianni P, et al.: Different pituitary beta-endorphin and adrenal cortisol response to ethanol in individuals with high and low risk for future development of alcoholism. Life Sci 1989, 45:1097-1109.
19. Jaffe AJ, Rounsaville B, Chang G, et al.: Naltrexone, relapse prevention, and supportive therapy with alcoholics: an analysis of patient treatment matching. J Consult Clin Psychol 1996, 64:1044-1053.
20. King AC, Schluger J, Gunduz M, et al.: Hypothalamic-pituitary-adrenocortical (HPA) axis response and biotransformation of oral naltrexone: preliminary examination of relationship to family history of alcoholism. Neuropsychopharmacology 2002, 26:778-788.
21. Monterosso JR, Flannery BA, Pettinati HM, et al.: Predicting treatment response to naltrexone: the influence of craving and family history. Am J Addict 2001, 10:258-268.
22. Mann K, Lehert P, Morgan MY: The efficacy of acamprosate in the maintenance of abstinence in alcohol-dependent individuals: results of a meta-analysis. Alcohol Clin Exp Res 2004, 28:51-63.
23. Mason BJ, Goodman AG, Chabac S, Lehert P: Effect of oral acamprosate on abstinence in patients with alcohol dependence in a double-blind, placebo-controlled trial: the role of patient motivation. J Psychiatr Res 2006, 40:383-393.
24. Brewer C: Controlled trials of antabuse in alcoholism: the importance of supervision and adequate dosage. Acta Psychitr Scand Suppl 1992, 369:51-58.
25. Fuller RK, Gordis E: Does disulfiram have a role in alcoholism treatment today? Addiction 2004, 99:21-24.
26. Johnson BA, Ait-Daoud N, Bowden CL, et al.: Oral topiramate for treatment of alcohol dependence: a randomised controlled trial. Lancet 2003, 361:1677-1685.
27. Johnson BA, Ait-Daoud N, Akhtar FZ, Ma JZ: Oral topiramate reduces the consequences of drinking and improves the quality of life of alcohol-dependent individuals. Arch Gen Psychiatry 2004, 61:905-912.
28. Pettinati HM, Kampman KM, Macfadden W, et al.: A randomized placebo-controlled pilot trial of quetiapine for the treatment of alcohol dependence. Paper presented at the 46th Annual New Clinical Drug Evaluation Unit Meeting. Boca Raton, FL; June 12-15, 2006.
29. Kiefer F, Jahn H, Tarnaske T, et al.: Comparing and combining naltrexone and acamprosate in relapse prevention of alcoholism. Arch Gen Psychiatry 2003, 60:92-99.
30. Anton RF, Moak DH, Waid LR, et al.: Naltrexone and cognitive behavioral therapy for the treatment of outpatient alcoholics: results of a placebo-controlled trial. Am J Psychiatry 1999, 156:1758-1764.
31. Pettinati HM, Volpicelli JR, Pierce JD, Jr, O'Brien CP: Improving naltrexone response: an intervention for medical practitioners to enhance medication compliance in alcohol dependent patients. J Addict Dis 2000, 19:71-83.
32. Pettinati HM, Weiss RD, Miller WR, et al.: Medical Management Treatment Manual: A Clinical Research Guide for Medically Trained Clinicians Providing Pharmacotherapy as Part of the Treatment for Alcohol Dependence. Bethesda, MD: US Department of Health and Human Services; 2004. NIAAA COMBINE Monograph Series, Vol 2. [DHHS publication no. 04-5289.]
33. Pettinati HM, Weiss RD, Dundon W, et al.: A structured approach to medical management: a psychosocial intervention to support pharmacotherapy in the treatment of alcohol dependence. J Stud Alcohol Suppl 2005, 15:170-178.
34. Volpicelli JR, Pettinati HM, McLellan AT, O'Brien CP: Combining Medication and Psychosocial Treatments for Addictions: The BRENDA Approach. New York: Guilford Press; 2001.
35. Weiss RD: Adherence to pharmacotherapy in patients with alcohol and opioid dependence. Addiction 2004, 99:1382-1392.
36. Kranzler HR, Modesto-Lowe V, Nuwayser ES: Sustained-release naltrexone for alcoholism treatment: a preliminary study. Alcohol Clin Exp Res 1998, 25:1335-1341.
37. Kranzler HR, Wesson DR, Billot L: Naltrexone depot for treatment of alcohol dependence: a multicenter, randomized, placebo-controlled clinical trial. Alcohol Clin Exp Res 2004, 28:1051-1059.
38. King AC, Volpicelli JR, Frazer A, O'Brien CP: Effect of naltrexone on subjective alcohol response in subjects at high and low risk for future alcohol dependence. Psychopharmacology 1997, 129:15-22.
39. Pettinati HM: Antidepressant treatment of co-occurring depression and alcohol dependence. Biol Psychiatry 2004, 56:785-792.
40. Harwood H: Updating Estimates of the Economic Costs of Alcohol Abuse in the United States: Estimates, Update Methods and Data. Bethesda, MD: National Institute on Alcohol Abuse and Alcoholism; 1998.
41. Grant BF, Dawson DA, Stinson FS: The 12-month prevalence and trends in DSM-IV alcohol abuse and dependence: United States, 1991-1992 and 2001-2002. Drug Alcohol Depend 2004, 74:223-234.